How To Make A Global First-In-Class Drug In China
The story so far of how an aspiring Western returnee researcher became a fully charged pharma entrepreneur in China’s wild world of drug innovation.
You may also be interested in...
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.
The successful IPO of China's drug innovation darling Betta may herald a new wave of capital inflow and renewed interest in new drug R&D in China, but hurdles to the pursuit of original research remain.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.